Clinical Trial Update: The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pegylated interferon alfa-2a plus ribavirin for chronic hepatitis C in non-genotype 2/3 patients; the study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2017-01-23